EXECUTIVE BOARD:

Salvatore Alesci, MD, PhD
VP Scientific Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA)

Elizabeth B. Andrews, MPH, PhD, F.I.S.P.E.
Vice President, Pharmacoepidemiology and Risk Management, RTI Health Solutions

Joseph M. Feczko, M.D.
Board of Directors, Foundation for the National Institutes of Health
Retired Senior Vice President and Chief Medical Officer, Pfizer, Inc.

Jesse L. Goodman, MD, MPH
Chief Scientist and Deputy Commissioner (Acting) for Science and Public Health, Food and Drug Administration

Steven J. Jacobsen, MD, PhD
Director of Research, Kaiser Permanente Southern California

Sangtae Kim, PhD
Director of Pharmaceutical Informatics, University of Wisconsin-Madison

Ronald L. Krall, MD
Former Senior Vice-President and Chief Medical Officer, GlaxoSmithKline

Richard Platt, MD, MSc
Professor and Chair of the Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care

N. Lee Rucker, M.S.P.H.
Senior Strategic Policy Advisor, AARP Public Policy Institute.

Brian L. Strom, MD, MPH
George S. Pepper Professor of Public Health and Preventive Medicine
Professor of Biostatistics and Epidemiology, Medicine, and Pharmacology
Chair, Department of Biostatistics and Epidemiology
Director, Center for Clinical Epidemiology and Biostatistics
Vice Dean for Institutional Affairs, University of Pennsylvania School of Medicine
Senior Advisor to the Provost for Global Health Initiatives, University of Pennsylvania

Myrl Weinberg
President, National Health Council

Marcus D. Wilson, Pharm.D.
President, HealthCore

Janet Woodcock, MD
Director, Center for Drug Evaluation and Research, Food and Drug Administration
OMOP Executive Board Chairperson

SCIENTIFIC ADVISORY BOARD:
The Scientific Advisory Board (SAB) provides independent review of and expert input into the scientific aspects of OMOP’s activities.

Andrew Bate, PhD
Pfizer, Senior Director, Quantitative Epidemiologist

Dr. Jesse Berlin
Johnson & Johnson Pharmaceutical R & D, Vice President, Epidemiology

Michael S. Katz
International Myeloma Foundation; Coalition of Cancer Cooperative Groups, Vice President; Chair, Patient Advisory Board

Dr. David Page
University of Wisconsin – Madison, Professor, Department of Biostatistics & Medical Informatics

Judith A. Racoosin, MD, MPH
Deputy Director for Safety
Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research, FDA

Kenneth J. Rothman, DrPH
RTI Health Solutions, RTI International, Research Triangle Park, NC, Distinguished Fellow and Vice President, Epidemiology Research; Boston University, Boston, MA, Professor of Epidemiology and Medicine

Judy A. Staffa, PhD, R.Ph
FDA/CDER/OSE, Associate Director for Regulatory Research

HEALTH INFORMATICS ADVISORY BOARD:
The Health Informatics Advisory Board (HIAB) provides independent review and expert input into the OMOP’s technology efforts related to privacy and security, terminology and coding, data, and data models.

Stanley M. Huff, MD
Intermountain Healthcare; University of Utah School of Medicine, Chief Medical Informatics Officer; Professor (clinical)

Diane T. MacKinnon
FDA (CDER), Patient Consultant

Dr. Clement J. McDonald
Director, Lister Hill Center for Biomedical Communications

Mitra Rocca
Associate Director, Medical Informatics
Food and Drug Administration